MX368261B - Letalidad sintetica y el tratamiento de cancer. - Google Patents

Letalidad sintetica y el tratamiento de cancer.

Info

Publication number
MX368261B
MX368261B MX2014000661A MX2014000661A MX368261B MX 368261 B MX368261 B MX 368261B MX 2014000661 A MX2014000661 A MX 2014000661A MX 2014000661 A MX2014000661 A MX 2014000661A MX 368261 B MX368261 B MX 368261B
Authority
MX
Mexico
Prior art keywords
cancer
treatment
methods
synthetic lethality
compounds
Prior art date
Application number
MX2014000661A
Other languages
English (en)
Other versions
MX2014000661A (es
Inventor
Luc G Berthiaume
Erwan Beauchamp
Conganige Maneka Anne Perinpanayagam
Chuiyee Yap
Original Assignee
Pacylex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacylex Pharmaceuticals Inc filed Critical Pacylex Pharmaceuticals Inc
Publication of MX2014000661A publication Critical patent/MX2014000661A/es
Publication of MX368261B publication Critical patent/MX368261B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos, composiciones y métodos para el tratamiento de cáncer. También se describen métodos y usos para identificar sujetos con cáncer que son apropiados para tratamientos con los compuestos, composición y métodos son descritos en la presente. En un aspecto de la presente invención, se provee un método de tratamiento de un sujeto que tiene cáncer deficiente de NMT2, que comprende administrar al sujeto un inhibidor de NMT.
MX2014000661A 2011-07-22 2012-07-23 Letalidad sintetica y el tratamiento de cancer. MX368261B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161510686P 2011-07-22 2011-07-22
PCT/CA2012/000696 WO2013013302A1 (en) 2011-07-22 2012-07-23 Synthetic lethality and the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2014000661A MX2014000661A (es) 2014-09-08
MX368261B true MX368261B (es) 2019-09-25

Family

ID=47600415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000661A MX368261B (es) 2011-07-22 2012-07-23 Letalidad sintetica y el tratamiento de cancer.

Country Status (16)

Country Link
US (3) US20140227284A1 (es)
EP (1) EP2734199B1 (es)
JP (1) JP6270719B2 (es)
KR (2) KR20140072026A (es)
CN (2) CN103826623A (es)
AU (2) AU2012286542A1 (es)
BR (1) BR112014001430A2 (es)
CA (1) CA2842443C (es)
DK (1) DK2734199T3 (es)
ES (1) ES2937269T3 (es)
IL (1) IL230575B (es)
MX (1) MX368261B (es)
PL (1) PL2734199T3 (es)
RU (1) RU2665952C2 (es)
SG (1) SG10201605814QA (es)
WO (1) WO2013013302A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6270719B2 (ja) 2011-07-22 2018-01-31 パシレックス・ファーマシューティカルズ・インコーポレイテッド 合成致死性および癌の治療
CN110974967B (zh) * 2012-10-30 2023-11-07 厄尔莱克斯制药公司 合成致死与癌症的治疗
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
JP7539760B2 (ja) * 2015-07-17 2024-08-26 パシレックス・ファーマシューティカルズ・インコーポレイテッド Ｎｍｔ２の後成的なサイレンシング
GB202017367D0 (en) * 2020-11-02 2020-12-16 Imperial College Innovations Ltd Novel use
WO2024052685A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2657259A1 (fr) * 1990-01-25 1991-07-26 Adir Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
PL2305221T3 (pl) 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
CN1905864B (zh) 2003-12-01 2011-04-06 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
NZ584288A (en) * 2004-02-06 2011-10-28 Elan Pharm Inc Methods and compositions for treating tumors and metastatic disease
SI1771474T1 (sl) * 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
WO2006086043A2 (en) 2004-11-23 2006-08-17 Science & Technology Corporation @ Unm Molecular technologies for improved risk classification and therapy for acute lymphoblastic leukemia in children and adults
ES2394925T3 (es) * 2005-09-27 2013-02-06 University Of Saskatchewan Uso de N-miristoiltransferasa en tejido no tumoral para el diagnóstico de cáncer
CN101631466B (zh) * 2006-12-18 2013-02-13 杰克·阿比瑟 新钯络合物体外抑制n-肉豆蔻酰基转移酶活性和体内抑制癌生长
GB0815947D0 (en) * 2008-09-02 2008-10-08 Univ Dundee Compounds
NZ737605A (en) 2011-07-22 2022-11-25 Pacylex Pharmaceuticals Inc Synthetic lethality and treatment of cancer
JP6270719B2 (ja) 2011-07-22 2018-01-31 パシレックス・ファーマシューティカルズ・インコーポレイテッド 合成致死性および癌の治療
CN110974967B (zh) 2012-10-30 2023-11-07 厄尔莱克斯制药公司 合成致死与癌症的治疗
JP7539760B2 (ja) 2015-07-17 2024-08-26 パシレックス・ファーマシューティカルズ・インコーポレイテッド Ｎｍｔ２の後成的なサイレンシング

Also Published As

Publication number Publication date
EP2734199A4 (en) 2015-04-01
ES2937269T3 (es) 2023-03-27
AU2012286542A1 (en) 2014-02-06
RU2014101787A (ru) 2015-08-27
IL230575A0 (en) 2014-03-31
DK2734199T3 (da) 2023-01-30
EP2734199B1 (en) 2022-11-16
CN103826623A (zh) 2014-05-28
US20190000838A1 (en) 2019-01-03
WO2013013302A8 (en) 2014-02-27
CN110115768A (zh) 2019-08-13
KR20140072026A (ko) 2014-06-12
JP2014523440A (ja) 2014-09-11
US20220023294A1 (en) 2022-01-27
BR112014001430A2 (pt) 2017-02-21
KR102164964B1 (ko) 2020-10-14
US12343341B2 (en) 2025-07-01
AU2018202839B2 (en) 2020-04-09
CA2842443A1 (en) 2013-01-31
JP6270719B2 (ja) 2018-01-31
IL230575B (en) 2021-07-29
MX2014000661A (es) 2014-09-08
AU2018202839A1 (en) 2018-05-10
SG10201605814QA (en) 2016-09-29
US11135218B2 (en) 2021-10-05
EP2734199A1 (en) 2014-05-28
WO2013013302A1 (en) 2013-01-31
US20140227284A1 (en) 2014-08-14
RU2665952C2 (ru) 2018-09-05
PL2734199T3 (pl) 2023-03-20
CA2842443C (en) 2022-01-25
KR20200093065A (ko) 2020-08-04

Similar Documents

Publication Publication Date Title
MX369609B (es) Una composición para usarse en el tratamiento de cáncer deficiente en nmt2.
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CO2019005287A2 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
MX2015011753A (es) Metodos para tratar cancer de vegija.
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
MX2019002303A (es) Inhibidores de procesos metabolicos celulares.
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
MX373925B (es) Tratamiento del cancer con inhibidores de tor cinasa.
MX2019010601A (es) Terapia de combinacion para tratar cancer.
MX373187B (es) Terapia de combinación para tratar cáncer.
MX2015014385A (es) Metodo para tratar trastorno de estres post-traumatico.
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112015011830A2 (pt) compostos e seus métodos de utilização
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BRPI1106572B8 (pt) Composições que compreendem um retinoide e um inibidor de nfkb e seus métodos de uso
CR20150483A (es) Composiciones y métodos para el diagnóstico y tratamiento del cáncer hepático
MX368261B (es) Letalidad sintetica y el tratamiento de cancer.
MX383365B (es) Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos.
MX2014008702A (es) Composiciones derivadas de la quitosana.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
GT201400038A (es) Composiciones y métodos para tratar el cáncer usando el inhibidor de p13kbeta y el inhibidor de la vía de mapk, incluidos los inhibidores de mek y raf

Legal Events

Date Code Title Description
FG Grant or registration